Where to buy Zanubrutinib

Zanubrutinib (Zanubrutinib) is a next-generation irreversible inhibitor of Bruton's tyrosine kinase (BTK), developed by BeiGene (BeiGene, China) in in 2012 for the treatment of B-cell malignant tumors, It is designed to minimize off-target inhibition of TEC family and EGFR family kinases. Zabrutinib is more selective than ibrutinib for BTK, EGFR, FGR, FRK, HER2, HER4, ITK, JAK3, LCK, BLK and TEC. In addition, zanubrutinib has better oral absorption and better target occupancy compared with ibrutinib.

Zabrutinibis similar to acalabrutinib and has lower activity against TEC and ITK. Preliminary Phase 1 results indicate that zanubrutinib is clinically active and that the drug is well tolerated in patients with B-cell lymphoid malignancies. Recent clinical trials found that it demonstrated excellent efficacy and good tolerability in patients with chronic lymphocytic leukemia (CLL), Waldenströmmacroglobulinemia(WM), and mantle cell lymphoma (MCL). In a recent phase 3 study, zanubrutinib was compared with ibrutinib in patients with relapsed/refractory (R/R) MW and RR CLL. In both trials, zanubrutinib b had a more clinically relevant safety and tolerability profile than ibrutinib; specifically, it was associated with a lower risk of atrial fibrillation/flutter and major bleeding events.

The original drug of zanubrutinib has been launched in China and has been included in the medical insurance. Specifications The price of 80mg*64 capsules per box may be around 6,000 yuan. This drug may be sold in domestic hospitals or pharmacies. Patients in need can consult local hospitals and other places. The original drug of zanubrutinib marketed overseas is relatively expensive, and there are currently no generic drugs of zanubrutinib on the market.